Perspectives on the Use of Adaptive Designs in Clinical Trials. Part II. Panel Discussion-Reference-Cited by-同舟云学术

Perspectives on the Use of Adaptive Designs in Clinical Trials. Part II. Panel Discussion

Published:2010-10-29 Issue:6 Volume:20 Page:1098-1112
ISSN:1054-3406
Container-title:Journal of Biopharmaceutical Statistics
language:en
Short-container-title:Journal of Biopharmaceutical Statistics

Author:

Benda Norbert¹,Brannath Werner²,Bretz Frank³,Burger Hans-Ulrich⁴,Friede Tim⁵,Maurer Willi³,Wang Sue-Jane⁶

Affiliation:

1. a Federal Institute for Drugs and Medical Devices , Bonn, Germany

2. b Medical University of Vienna , Vienna, Austria

3. c Statistical Methodology , Novartis Pharma AG , Basel, Switzerland

4. d Hoffmann-La Roche , Basel, Switzerland

5. e University Medical Center Göttingen , Göttingen, Germany

6. f U.S. Food and Drug Administration , Silver Spring, Maryland, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/10543406.2010.514447

Reference26 articles.

1. Adaptive designs: Looking for a needle in the haystack—A new challenge in medical research

2. Aspects of Modernizing Drug Development Using Clinical Scenario Planning and Evaluation

3. Unbiased Estimation of Selected Treatment Means in Two-Stage Trials

4. Brannath , W. König , F. ( 2008 ). Estimation after treatment selection. Talk at Joint the LifeStat Conference (Meeting of German and Austrian Region of the Biometrical Society), Munich .

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stakeholder perspectives on adaptive clinical trials: a scoping review;Trials;2020-06-17

2. Adaptive design of confirmatory trials: Advances and challenges;Contemporary Clinical Trials;2015-11

3. Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice;Trials;2015-04-22

4. When is a seamless study desirable? Case studies from different pharmaceutical sponsors;Pharmaceutical Statistics;2014-05-29

5. A Commentary on the U.S. FDA Adaptive Design Draft Guidance and EMA Reflection Paper from a Regulatory Perspective and Regulatory Experiences;Practical Considerations for Adaptive Trial Design and Implementation;2014